NCT07651644Recruiting
Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
Protocol for a Prospective Randomised Crossover Controlled Trial of the Artificial Intelligence-Assisted Decision-Making System for Gastric Cancer T-Staging (TRACE)
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
This study employed a prospective, randomised crossover trial design to evaluate the clinical utility of the TRACE artificial intelligence system for gastric cancer T-staging. A total of 54 radiologists from tertiary and non-tertiary hospitals, including both senior and junior practitioners, were enrolled. The study aimed to investigate whether AI-assisted diagnosis could improve the diagnostic accuracy of gastric cancer T-staging compared with independent interpretation by radiologists. All participants were required to interpret 60 contrast-enhanced CT cases sequentially, completing two readings for each case: one without AI assistance and one with AI assistance; The order of the two readings was randomised, and a one-month washout period was observed between readings to eliminate memory bias. All cases were pathologically confirmed gastric cancer cases (stages T1-T4b), and the study simultaneously recorded the physicians' T-staging diagnostic results and the time taken per case. The 60 cases per radiologist were randomly selected from a pool of 1,000 histologically confirmed gastric cancer cases, stratified by pathological T stage T1-T4b. The reference standard was postoperative pathological T stage. The primary outcome was the change in T-staging accuracy between AI-assisted reading and standard (unaided) reading.The term "prospective" in this study refers to the prospective execution of radiologist enrollment, randomization, reading procedures, and data collection.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- Jun 2026
- Primary completion date
- Jul 2026
- Lead sponsor
- Liaoning Cancer Hospital & Institute
- NCT number
- NCT07651644
What you commit to
- Study type: Interventional
- Planned participants: 54
- From Jun 2026 to the primary completion date, Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Contrast-enhanced CT (CE-CT) images of gastric cancer patients from the Liaoning Cancer Hospital;
- Patients with a definitive postoperative pathological diagnosis of gastric cancer and a clear T-stage classification (T1-T4, including T4a and T4b);
- Imaging data must be complete and of sufficient quality to meet diagnostic and analytical requirements, with no significant artefacts or missing key data;
- Complete clinical and pathological information must be available to establish a diagnostic gold standard for comparison.
- Physician Inclusion Criteria (Image Readers)
- Radiologists holding a valid medical licence;
- From the radiology department of a Grade A tertiary hospital or a non-Grade A tertiary hospital;
- Classified as senior or junior physicians based on clinical experience;
- Voluntarily participating in this study and completing both the non-AI-assisted and AI-assisted image interpretation tasks.
- Case Exclusion Criteria
- Severe missing imaging data or quality failing to meet analysis requirements (e.g., severe motion artefacts);
- Lack of clear postoperative pathological T-staging results;
- Cases not involving gastric cancer or with incomplete pathological information;
- Cases of duplicate enrolment or inconsistent data recording.
- Physician Exclusion Criteria
- Those unable to complete all image review tasks or demonstrating severe non-compliance;
- Those who withdraw during the study period and are unable to provide complete data for both phases of image review;
- Those who fail to complete the AI-assisted and non-AI-assisted interpretation processes as specified.
- Withdrawal Criteria
- Physicians who voluntarily withdraw from the study for personal reasons (e.g., time, health or work commitments);
- Physicians who fail to complete the required image review tasks or have data missing in excess of the specified threshold;
- Cases where critical data errors are identified during subsequent verification or where pathological results cannot be traced; Data found during the study to be non-compliant with ethical or quality control requirements must be excluded.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital & Institute) Coordinator of this site? Confirm its status | Shenyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.